Pancreatic Cancer Research

ResearcherUniversitätsmedizin GreifswaldNo recent work listed

Frank Ulrich Weiß

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3369-6369; OpenAlex author ID A5009296138. Sources: OpenAlex.

Their work

Papers
26 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
67
Papers, trials and grants by year

2011: 4 papers · 2012: 2 papers · 2013: 1 paper · 2014: 2 papers · 2015: 1 paper · 2016: 3 papers · 2017: 3 papers · 2018: 3 papers · 2019: none · 2020: 1 paper · 2021: 2 papers · 2022: 4 papers

Papers 26

  1. Independent Validation and Assay Standardization of Improved Metabolic Biomarker Signature to Differentiate Pancreatic Ductal Adenocarcinoma From Chronic Pancr… Co-author DOI 10.1053/j.gastro.2022.07.047↗
  2. Inhibition of KRAS, MEK and PI3K Demonstrate Synergistic Anti-Tumor Effects in Pancreatic Ductal Adenocarcinoma Cell Lines. Co-author DOI 10.3390/cancers14184467↗
  3. The Inhibitory Response to PI3K/AKT Pathway Inhibitors MK-2206 and Buparlisib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell Lines. Co-author DOI 10.3390/ijms23084295↗
  4. Inhibitory Response to CK II Inhibitor Silmitasertib and CDKs Inhibitor Dinaciclib Is Related to Genetic Differences in Pancreatic Ductal Adenocarcinoma Cell L… Co-author DOI 10.3390/ijms23084409↗
  5. Tumor-Specific Delivery of 5-Fluorouracil-Incorporated Epidermal Growth Factor Receptor-Targeted Aptamers as an Efficient Treatment in Pancreatic Ductal Adenoc… Co-author DOI 10.1053/j.gastro.2021.05.055↗
  6. Plasma Metabolome Profiling Identifies Metabolic Subtypes of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cells10071821↗
  7. Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1093/jncics/pkz060↗
  8. Plasma protein profiling of patients with intraductal papillary mucinous neoplasm of the pancreas as potential precursor lesions of pancreatic cancer. Co-author DOI 10.1016/j.cca.2017.12.008↗
  9. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2018.08.009↗
  10. Metabolic biomarker signature to differentiate pancreatic ductal adenocarcinoma from chronic pancreatitis. Co-author DOI 10.1136/gutjnl-2016-312432↗
  11. Copy number variants and VNTR length polymorphisms of the carboxyl-ester lipase (CEL) gene as risk factors in pancreatic cancer. Co-author DOI 10.1016/j.pan.2016.10.006↗
  12. LPS promotes resistance to TRAIL-induced apoptosis in pancreatic cancer. Co-author DOI 10.1186/s13027-017-0139-4↗
  13. Subdiaphragmatic vagotomy promotes tumor growth and reduces survival via TNFα in a murine pancreatic cancer model. Co-author DOI 10.18632/oncotarget.15019↗
  14. Chronic stress increases experimental pancreatic cancer growth, reduces survival and can be antagonised by beta-adrenergic receptor blockade. Co-author DOI 10.1016/j.pan.2016.03.005↗
  15. Tumour-specific delivery of siRNA-coupled superparamagnetic iron oxide nanoparticles, targeted against PLK1, stops progression of pancreatic cancer. Co-author DOI 10.1136/gutjnl-2016-311393↗
  16. Development of Pancreatic Cancer: Targets for Early Detection and Treatment. Co-author DOI 10.1159/000445233↗
  17. Surgical trauma leads to a shorter survival in a murine orthotopic pancreatic cancer model. Co-author DOI 10.1159/000368226↗
  18. Metabolic biomarkers for the differential diagnosis of pancreatic ductal adenocarcinoma vs. chronic pancreatitis Co-author DOI 10.1186/2049-3002-2-s1-p60↗
  19. Pancreatic cancer risk in hereditary pancreatitis. Co-author DOI 10.3389/fphys.2014.00070↗
  20. Induction of M2-macrophages by tumour cells and tumour growth promotion by M2-macrophages: a quid pro quo in pancreatic cancer. Co-author DOI 10.1016/j.pan.2013.06.010↗
  21. Recruitment of histone deacetylases HDAC1 and HDAC2 by the transcriptional repressor ZEB1 downregulates E-cadherin expression in pancreatic cancer. Last author DOI 10.1136/gutjnl-2011-300060↗
  22. Tissue tolerable plasma (TTP) induces apoptosis in pancreatic cancer cells in vitro and in vivo. Co-author DOI 10.1186/1471-2407-12-473↗
  23. Drug efflux transporter multidrug resistance-associated protein 5 affects sensitivity of pancreatic cancer cell lines to the nucleoside anticancer drug 5-fluor… Co-author DOI 10.1124/dmd.110.033613↗
  24. Environmental risk factors for chronic pancreatitis and pancreatic cancer. Co-author DOI 10.1159/000323933↗
  25. A syngeneic orthotopic murine model of pancreatic adenocarcinoma in the C57/BL6 mouse using the Panc02 and 6606PDA cell lines. Co-author DOI 10.1159/000329413↗
  26. In vivo imaging of pancreatic tumours and liver metastases using 7 Tesla MRI in a murine orthotopic pancreatic cancer model and a liver metastases model. Co-author DOI 10.1186/1471-2407-11-40↗

Closest collaborators

The 25 strongest of 67 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Markus M. Lerch · 19 shared papers, 2011–2022 · strength 1.30
  2. Julia V. Mayerle · 17 shared papers, 2011–2022 · strength 0.95
  3. Ujjwal Mukund Mahajan · 8 shared papers, 2016–2022 · strength 0.61
  4. Georg Beyer · 6 shared papers, 2018–2022 · strength 0.51
  5. Yixuan Ma · 3 shared papers, 2022 · strength 0.40
  6. Dietmar Zechner · 3 shared papers, 2022 · strength 0.40
  7. Hugo Murua Escobar · 3 shared papers, 2022 · strength 0.40
  8. Ivonne Regel · 4 shared papers, 2018–2022 · strength 0.36
  9. Elisabetta Goni · 4 shared papers, 2018–2022 · strength 0.34
  10. Wolfram von Bernstorff · 8 shared papers, 2011–2017 · strength 0.33
  11. Robert Grützmann · 4 shared papers, 2014–2022 · strength 0.31
  12. Christian P. Pilarsky · 4 shared papers, 2014–2022 · strength 0.31
  13. Lars Ivo Partecke · 6 shared papers, 2011–2017 · strength 0.28
  14. Marius Distler · 3 shared papers, 2018–2022 · strength 0.27
  15. John P. Neoptolemos · 3 shared papers, 2018–2022 · strength 0.24
  16. Holger Kalthoff · 3 shared papers, 2014–2022 · strength 0.21
  17. Waldemar H. Uhl · 2 shared papers, 2021–2022 · strength 0.21
  18. Fritz Klein · 2 shared papers, 2021–2022 · strength 0.21
  19. Kirsten Lauber · 2 shared papers, 2021 · strength 0.19
  20. Katharina Beyer · 3 shared papers, 2016–2017 · strength 0.19
  21. André Käding · 5 shared papers, 2011–2017 · strength 0.18
  22. Roland Rad · 2 shared papers, 2018–2022 · strength 0.16
  23. Markus Wolfgang Büchler · 3 shared papers, 2012–2020 · strength 0.16
  24. Péter Simon · 3 shared papers, 2011–2017 · strength 0.14
  25. Robert Jaster · 1 shared paper, 2022 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.